Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 7/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | GCK | P35557 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5239807 | 0.98 | HCAR3 (0.68) | HCAR3MEN1KMT2ANPC1RAB9A | |
| SCHEMBL30498440 | 0.92 | HCAR3 (0.66) | HCAR3NPC1RAB9AALDH1A1GCK | |
| SCHEMBL21061901 | 0.92 | HCAR3 (0.66) | HCAR3NPC1RAB9AALDH1A1GCK | |
| SCHEMBL5236756 | 0.87 | NPC1 (0.60) | HCAR3MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5233668 | 0.85 | NPC1 (0.57) | HCAR3MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5738821 | 0.82 | HCAR3 (0.54) | HCAR3MEN1KMT2ANPC1RAB9A | |
| SCHEMBL8115278 | 0.81 | HCAR3 (0.97) | HCAR3 | |
| SCHEMBL29518875 | 0.81 | DEGS1 (0.66) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL20284163 | 0.81 | DEGS1 (0.66) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL5239996 | 0.80 | HCAR3 (0.59) | HCAR3MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0804440-B1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | WYETH CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-0804438-B1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | WYETH CORP (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-0811008-B1 | BICYCLIC BENZAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | WYETH CORP (US) | 2003-10-01 | — | — | EP | disclosed |
| CN-1065244-C | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID CO (US) | 2001-05-02 | — | — | CN | disclosed |
| CN-1061658-C | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID CO (US) | 2001-02-07 | — | — | CN | disclosed |
| CN-1231666-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID CO (US) | 1999-10-13 | — | — | CN | disclosed |
| US-5849735-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| CN-1198746-A | Tricyclic benzazepine * vasopressin antagonists | AMERICAN CYANAMID CO (US) | 1998-11-11 | — | — | CN | disclosed |
| US-5753648-A | THREATING DISEASES CAUSED BY RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1998-05-19 | — | — | US | disclosed |
| US-5719278-A | TREATING EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1998-02-17 | — | — | US | disclosed |
| US-5700796-A | USEFUL FOR TREATING CONGESTIVE HEART FAILURE, DISEASE CONDITIONS WITH EXCESS RENAL WATER REABSORPTION AND CONDITIONS WITH INCREASED VASULAR RESISTANCE AND CORONARY VASOCONSTRICTION | AMERICAN CYANAMID COMPANY (US) | 1997-12-23 | — | — | US | disclosed |
| US-5696112-A | TREATMENT OF CONGESTIVE HEART FAILURE, CORONARY VASOCONSTRICTION | AMERICAN CYANAMID COMPANY (US) | 1997-12-09 | — | — | US | disclosed |
| US-5654297-A | CONGESTIVE HEART FAILURE, CARDIOVASCULAR DISORDERS | AMERICAN CYANAMID COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| US-5612334-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5610156-A | USED IN TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| WO-1996022293-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996022294-A1 | BICYCLIC BENZAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996022282-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5536718-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1996-07-16 | — | — | US | disclosed |
| US-5532235-A | TO TREAT EXCESS RENAL REABSORPTION | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |